Autolus Therapeutics plc (AUTL)
- Previous Close
2.3400 - Open
2.3150 - Bid 2.3000 x 700
- Ask 2.9500 x 200
- Day's Range
2.2950 - 2.3799 - 52 Week Range
1.1750 - 2.5800 - Volume
1,168,072 - Avg. Volume
1,905,693 - Market Cap (intraday)
625.482M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0600 - Earnings Date Nov 16, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.73
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
www.autolus.com752
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News
View MorePerformance Overview
Trailing total returns as of 2026-09-01, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
Market Cap
628.14M
Enterprise Value
510.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.35
Price/Book (mrq)
8.39
Enterprise Value/Revenue
4.34
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.27%
Return on Equity (ttm)
-29.62%
Revenue (ttm)
1.08M
Net Income Avi to Common (ttm)
-53.28M
Diluted EPS (ttm)
-1.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
217.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.